Takeda entered a multiyear partnership with AI drug discovery company Iambic to accelerate small-molecule programs across oncology, gastrointestinal, and inflammatory targets. The collaboration will leverage Iambic’s model-driven chemistry capabilities to complement Takeda’s discovery engines and target selection. Takeda framed the deal as part of a broader strategy to integrate advanced AI tools into R&D. Company executives highlighted a need to fully embed AI across discovery workflows to remain competitive, and the pact underscores sustained pharma investment in computational drug-design partnerships.